Jeligo (Linagliptin)

Linagliptin works by selectively inhibiting the dipeptidyl peptidase‑4 (DPP‑4) enzyme, which results in increased levels of the incretin hormones GLP‑1 and GIP. These hormones stimulate glucose‑dependent insulin secretion and suppress glucagon release, thereby lowering blood glucose concentrations after meals and during fasting.

The dose of Jeligo is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function and concomitant therapies. Patients should follow the prescriber’s instructions exactly and should not alter the dose without medical advice.

Safety of linagliptin in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and such decisions must be made by the treating physician.

To place an order, submit an enquiry on the Jeligo product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other DPP‑4 inhibitors, linagliptin has a long half‑life that allows once‑daily dosing without the need for dose adjustment in renal impairment, whereas some alternatives require renal dose modifications. Efficacy and overall safety are broadly comparable across the class.

Jeligo tablets should be stored at ambient temperature below 25 °C, in the original blister pack, protected from moisture and direct sunlight. Keep the medication out of reach of children and do not use after the expiry date.

Jeligo is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and should not be crushed, chewed, or broken.

Serious but rare adverse reactions include pancreatitis, severe hypersensitivity reactions such as anaphylaxis, and hepatic injury. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling, or signs of liver dysfunction such as jaundice.

Jeligo is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or a known hypersensitivity to linagliptin or any excipients in the formulation. Caution is also advised for patients with severe hepatic impairment, and the drug should be used only under medical supervision in such cases.